Mesoblast aims to generate a series of high margin, off-the-shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Mesoblast listed on the Australian Securities Exchange (ASX: MSB) in December 2004.
In December 2010, Mesoblast completed its acquisition of United States company, Angioblast Systems Inc. This strategic acquisition enabled Mesoblast to broaden its product pipeline across a wider range of clinical indications including cardiovascular, oncology, eye diseases, and diabetes, in addition to its orthopedic range of products.
Also in December 2010, Mesoblast formed a strategic alliance with global biopharmaceutical company, Cephalon Inc., to develop and commercialize its novel adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include congestive heart failure, acute myocardial infarction, stroke, Parkinson’s disease and Alzheimer’s disease. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Cephalon is funding all late stage clinical development costs worldwide for the specific products, as well as all sales and marketing costs. Mesoblast retains all manufacturing rights and will sell finished products to Cephalon on a transfer price basis.